Some 64 sites are now enrolling test subjects for Voyager Pharmaceutical’s Phase 3 trial of a proposed Alzheimer’s disease.
The trial, dubbed “Aladdin” by Voyager, is testing the compound VP4896, which is intended to treat middle to moderate Alzheimer’s.
Some 64 sites are enrolling patients. Of those, 53 are in the United States and Canada. The other 11 are in Australia. Some 57 subjects have been enrolled, and Voyager said the enrollment is ahead of schedule.
Voyager wants to enroll 555 subjects for the trial.